November 13, 2026

To all stakeholders,

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE
email: ir@ppmx.com

Notice Regarding the Recognition of Non-operating Income, Non-operating Expenses, and Extraordinary Losses

Perseus Proteomics Inc. (the "Company") announces that it recognized non-operating income, non-operating expenses, and extraordinary losses for the six months ended September 30, 2026, as described below.

1. Details of Non-operating Income

   The Company recognized subsidy income of 19,316 thousand yen and insurance income of 10,000 thousand yen and interest income of 3,329 thousand yen as non-operating income.

2. Details of Non-operating Expenses

   The Company recognized sickness allowance of 10,000 thousand yen and foreign exchange losses of 3,790 thousand yen and share issuance costs of 2,328 thousand yen as non-operating expenses.

3. Details of Extraordinary Losses

   The Company recognized an impairment loss of 4,024 thousand yen on its fixed assets as an extraordinary loss in accordance with the Accounting Standard for Impairment of Fixed Assets.

4. Impact on Financial Results

   The above items are reflected in the "Non-consolidated Financial Results for the Six Months Ended September 30, 2026 (Under Japanese GAAP)" announced today.